The Phase 2b trial is expected to investigate the efficacy, safety and tolerability of two dose levels of a single application of DeOvo compared to vehicle.
The primary endpoint of the trial is the proportion of all subjects who are lice free at all follow-up visits through the Day 14 visit.
Hatchtech chairman Paul Kelly said DeOvo is a next generation head lice treatment therapy that targets all life cycle stages of the parasite with a single 10 minute application.
"We have previously demonstrated that this agent effectively treats eggs and crawling lice in a small number of infested adults. Now we are assessing the compound in a larger clinical trial including adult and pediatric subjects," Kelly said.